CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Journal
Overview
publication venue for
- ALPHA2: A Phase 1b Study Evaluating the CD19 Allogeneic CAR T Cell Product Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Relapsed/ Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) 2024
- ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First-Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema- Cel) in Patients With Large B-Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy 2024
- Hemophagocytic Lymphohistiocytosis Co-Presenting With Non-Cirrhotic Portal Hypertensive Gastropathy: A Case Report 2024
- Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) 2023
- Treatment Options for Bronchiolitis Obliterans After Hematopoietic Stem Cell Transplant: A Systematic Review of Clinical Trials in the Last 10 years 2023
- Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy. 19:E93-E97. 2019
Research
category
- HEMATOLOGY Web of Science Category
- ONCOLOGY Web of Science Category
Identity
International Standard Serial Number (ISSN)
- 2152-2650
Electronic International Standard Serial Number (EISSN)
- 2152-2669
Other
journal abbreviation
- CL LYMPH MYELOM LEUK